pAMP Platform
Proprietary multi-epitope concatemeric peptide technology delivering broad immune coverage against complex pathogens.
Delaware, USA · Programmable Platform Biotechnology
Engineering the Next Generation of Vaccines and Therapeutics
Kinexar Bio is a biopharmaceutical company developing next-generation vaccines and therapeutics, powered by its patented, programmable platform for designing high-density, multi-epitope biological constructs, with initial focus on high-consequence infectious diseases and biodefense.
The Gap
High-consequence pathogens still have no countermeasures.
Emerging and weaponizable pathogens outpace conventional vaccine development. Kinexar Bio's patented platform is purpose-built for the threats where speed, stability, and breadth of immune coverage matter most — and where no approved vaccine exists today.
35–40%
Case fatality rate of Hantavirus Pulmonary Syndrome (ANDV)
Zero
FDA-approved vaccines or therapeutics for HPS
2026
Multi-country ANDV outbreak on MV Hondius cruise ship — declared by WHO, underscoring urgent need for countermeasures
No cold chain
Recombinant protein subunit platform — no ultra-cold storage required
Platform
Built on the Patented pAMP Platform
A patented, programmable concatemeric architecture that assembles multiple precision immune targets into a single, manufacturable construct.
Concatemeric Assembly
Enables precise, programmable assembly of repeating bioactive peptide units, producing non-replicating vaccine and therapeutic constructs.
Thermostable
Cold-chain independent formulation suitable for field deployment in resource-limited settings.
Scalable Manufacturing
Compatible with standard recombinant protein production — no live virus, no complex biologics infrastructure required.
Proven Versatility
Platform has demonstrated biological activity across multiple indications including infectious disease and wound healing applications.
Non-Replicating
No live or attenuated virus in the construct, supporting a favorable safety profile and streamlined biosafety handling.
Pipeline Snapshot
Lead program: KNX-001 for Hantavirus Pulmonary Syndrome
A pAMP-based vaccine candidate against Andes virus (ANDV), designed to elicit broad neutralizing antibody and T-cell responses.
| Program | Pathogen | Indication | Stage | Funding Pathway |
|---|---|---|---|---|
| KNX-001 | Andes Virus (ANDV) | Hantavirus Pulmonary Syndrome (HPS) | Preclinical | Government MCM |
Swipe the table horizontally to see all columns.
Leadership
Experienced leaders building the next generation of vaccines and therapeutics
Devrim Aran
President & Chief Executive Officer
Biopharmaceutical executive and entrepreneur with a track record spanning drug development, regulatory strategy, clinical trials, and international licensing. He has led multiple biopharmaceutical ventures from inception through clinical development, raising capital and building strategic partnerships across the United States and Europe. At Kinexar Bio, he leads all corporate, business development, and regulatory operations.
Dr. Omar Ahmed
Chief Scientific Officer & Chief Strategy Officer
Scientific and strategic leader with a proven track record across clinical, medical affairs and commercialization, overseeing Kinexar's scientific direction, research strategy and external collaborations. His work bridges cutting-edge academic research and commercial drug development, ensuring the patented pAMP platform advances efficiently from preclinical studies toward regulatory milestones.
Partner with Kinexar Bio
We welcome inquiries from government program officers, strategic partners, and investors.